Ancell

anti-CD272 [BTLA] (human), mAb (ANC6E9)

CHF 306.00
In stock
ANC-272-020100 µgCHF 306.00
More Information
Product Details
Synonyms BTLA; B- and T-lymphocyte Attenuator
Product Type Monoclonal Antibody
Properties
Clone ANC6E9
Isotype Mouse IgG1κ
Immunogen/Antigen Recombinant extracellular human CD272.
Application

ELISA
Flow Cytometry
Functional Application

Crossreactivity Human
Formulation 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5mg/ml Gentamicin sulfate
Isotype Negative Control

Mouse IgG1 Isotype Control

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by Ancell Corporation.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at +4°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Human CD272 (BTLA; B and T Lymphocyte Attenuator) is a member of the immunoglobulin superfamily and has sequence homology to PD-1 and CTLA-4. It is expressed on T and B lymphocytes and other hemopoetic lineages. Engagement of this molecule by its ligand CD270 (HVEM) can downregulate activated T and B cell responses. CD272 levels on antigen specific CD8+ T cells have been reported to decrease in viral specific, but not melanoma specific activated lines. Polymorphism of the CD272 molecule has been linked to rheumatoid arthritis.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.